Fear of Missing Organisms (FOMO): the discordance among broad-spectrum empiric antibiotic therapy, microbiologic results, and definitive antibiotic therapy for diabetic foot infections and lower extremity osteomyelitis.


Journal

Antimicrobial stewardship & healthcare epidemiology : ASHE
ISSN: 2732-494X
Titre abrégé: Antimicrob Steward Healthc Epidemiol
Pays: England
ID NLM: 9918266096106676

Informations de publication

Date de publication:
2023
Historique:
received: 13 07 2023
revised: 30 08 2023
accepted: 06 09 2023
medline: 29 11 2023
pubmed: 29 11 2023
entrez: 29 11 2023
Statut: epublish

Résumé

Empiric broad-spectrum antibiotic therapy is commonly prescribed for patients hospitalized with diabetic foot infections (DFI) and lower extremity osteomyelitis (OM). The primary objective was to evaluate the concordance between empiric antibiotic therapy, microbiologic results, and definitive antibiotic therapy with a focus on methicillin-resistant Retrospective cohort study. Safety-net health system in Ohio. Adults hospitalized and receiving antibiotic therapy for DFI or lower extremity OM in 2021. For 259 unique patients, empiric therapies with activity against MRSA and resistant gram-negative organisms were administered to 224 (86.5%) and 217 (83.8%) patients, respectively. Definitive therapies with activity against MRSA and resistant gram-negative organisms were administered to 91 (35%) and 74 (28.6%) patients, respectively. Of 234 patients with microbiologic testing, 29 (12.4%) had positive cultures with MRSA and 41 (17.5%) with resistant gram-negative organisms. The NPVs of risk factors for MRSA and resistant gram-negative organisms for the absence of these organisms in culture were 91% and 85%, respectively. For patients hospitalized with DFI and lower extremity OM, our data suggest opportunities for substantial reductions in empiric therapies with activity against MRSA and resistant gram-negative organisms. The absence of risk factors for these organisms was reasonably good at predicting negative cultures with these organisms.

Identifiants

pubmed: 38028912
doi: 10.1017/ash.2023.467
pii: S2732494X23004679
pmc: PMC10654958
doi:

Types de publication

Journal Article

Langues

eng

Pagination

e186

Informations de copyright

© The Author(s) 2023.

Déclaration de conflit d'intérêts

All authors report no conflicts of interest relevant to this article.

Références

Antimicrob Steward Healthc Epidemiol. 2023 Mar 02;3(1):e39
pubmed: 36960089
Clin Infect Dis. 2012 Jun;54(12):e132-73
pubmed: 22619242
Open Forum Infect Dis. 2018 Sep 27;5(11):ofy245
pubmed: 30402532
Antimicrob Agents Chemother. 2020 Mar 24;64(4):
pubmed: 31988097
Ther Adv Endocrinol Metab. 2018 Jan;9(1):29-31
pubmed: 29344337
PLoS One. 2016 Aug 24;11(8):e0161658
pubmed: 27556897
Intern Med J. 2019 Apr;49(4):533-536
pubmed: 30957374
Int J Infect Dis. 2017 Jun;59:61-64
pubmed: 28450198
Open Forum Infect Dis. 2022 Jun 17;9(7):ofac297
pubmed: 35873292
Am J Respir Crit Care Med. 2019 Oct 1;200(7):e45-e67
pubmed: 31573350
Diabetes Metab Res Rev. 2020 Mar;36 Suppl 1:e3280
pubmed: 32176444
Foot (Edinb). 2022 Sep;52:101909
pubmed: 36049265

Auteurs

Morgan K Morelli (MK)

Department of Medicine, Division of Infectious Diseases and HIV Medicine, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, OH, USA.
Department of Medicine, Division of Infectious Disease, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.

Andrea H Son (AH)

Department of Pharmacy, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.

Yanis Bitar (Y)

Department of Medicine, Division of Infectious Disease, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.

Michelle T Hecker (MT)

Department of Medicine, Division of Infectious Disease, The MetroHealth System, Case Western Reserve University, Cleveland, OH, USA.

Classifications MeSH